TRAX
First Tracks Biotherapeutics, Inc.
Set alert
45.08 USD -0.15 -0.32%
43.36 Day range 45.87
15.32 52-week range 47.92
- YTD
- +137.26%
- 1 year
- +137.26%
- Open
- 45.03
- Prev close
- 45.23
- Mkt cap
- 1.89B
- Vol
- 434.20K
- Avg vol
- 833.99K
- EPS
- -4.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.36
- High
- 45.87
- Forward P/E
- -12.45
- Beta
- 0.00
- Short ratio
- 6.01
- Inst. own
- 88.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 38.86
- 200-d avg
- 30.42
- 1y target
- 74.17
Key statistics
- Market cap
- 1.89B
- Enterprise value
- 1.45B
- Trailing P/E
- 0.00
- Forward P/E
- -12.45
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.45
- EPS (TTM)
- -4.71
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 168.02M
- Total debt
- 4.33M
- Return on equity
- 0.00%
- Shares outstanding
- 42.02M
- Short % of float
- 0.00%
- 50-day average
- 38.86
- 200-day average
- 30.42
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 74.17 +64.5% upside
Now 45.08
- Target (low)
- 57.00
- Target (mean)
- 74.17
- Target (high)
- 100.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy3
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.88545.
Financials — quick view
TRAX Revenue — quarterly 0
TRAX Net income — quarterly -33.37M
TRAX EPS — quarterly -0.95
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.92 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.80256 | -0.95 | -0.15 | -18.37% |
| May 14, 2026 | Mar 31, 2026 | -0.98059 | -1.45 | -0.47 | -47.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 13, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 13, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 13, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 30, 2026 | Canaccord Genuity | init | — | Buy |
| Sep 18, 2026 | Evercore ISI Group | init | — | Outperform |
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- firsttracksbio.com
News
- Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90
- First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors
- First Tracks Biotherapeutics Announces $200 Million Private Placement
- First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
- Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60
- Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70
- Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70
- First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
- First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals
- Dow Gains Over 200 Points; Chipotle Shares Move Lower
Your note
Sign in to keep a note on TRAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 19, 2026 | 0 |
| FENTON DENNIS M | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 10,995 |
| JAIN RITA | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 19,194 |
| JOE ANTHONY WARE | Director | Sale | Sep 1, 2026 | 15,660 |
| MARQUET MAGDA | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 15,960 |
| ORWIN JOHN A | Director | Conversion of Exercise of derivative security | Sep 14, 2026 | 17,995 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.56% | 3,174,519 | 143.11M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 6.89% | 2,895,304 | 130.52M | Jun 29, 2026 |
| FMR, LLC | 4.89% | 2,054,127 | 92.60M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 4.84% | 2,032,012 | 91.60M | Jun 29, 2026 |
| Blackrock Inc. | 4.67% | 1,963,541 | 88.52M | Jun 29, 2026 |
| Trails Edge Capital Partners, LP | 3.60% | 1,514,000 | 68.25M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.65% | 1,111,470 | 50.11M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.08% | 874,168 | 39.41M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.06% | 865,021 | 39.00M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.95% | 400,000 | 18.03M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.74% | 309,285 | 13.94M | Jun 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.69% | 290,000 | 13.07M | Jul 30, 2026 |